Biofrontera Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $8.3
- Today's High:
- $8.3685
- Open Price:
- $8.3685
- 52W Low:
- $0.37
- 52W High:
- $2.712
- Prev. Close:
- $8.3
- Volume:
- 1085
Company Statistics
- Market Cap.:
- $12.42 million
- Book Value:
- 0.627
- Revenue TTM:
- $27.66 million
- Operating Margin TTM:
- -83.07%
- Gross Profit TTM:
- $13.49 million
- Profit Margin:
- -49.46%
- Return on Assets TTM:
- -31.5%
- Return on Equity TTM:
- -80.07%
Company Profile
Biofrontera Inc had its IPO on 2021-10-29 under the ticker symbol BFRI.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Biofrontera Inc has a staff strength of 81 employees.
Stock update
Shares of Biofrontera Inc opened at $8.37 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $8.3 - $8.37, and closed at $8.3.
This is a 0% increase from the previous day's closing price.
A total volume of 1,085 shares were traded at the close of the day’s session.
In the last one week, shares of Biofrontera Inc have slipped by -2.7%.
Biofrontera Inc's Key Ratios
Biofrontera Inc has a market cap of $12.42 million, indicating a price to book ratio of 1.1282 and a price to sales ratio of 0.8579.
In the last 12-months Biofrontera Inc’s revenue was $27.66 million with a gross profit of $13.49 million and an EBITDA of $-22460000. The EBITDA ratio measures Biofrontera Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Biofrontera Inc’s operating margin was -83.07% while its return on assets stood at -31.5% with a return of equity of -80.07%.
In Q1, Biofrontera Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 10.4%.
Biofrontera Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.64 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biofrontera Inc’s profitability.
Biofrontera Inc stock is trading at a EV to sales ratio of 2.0359 and a EV to EBITDA ratio of -4.934. Its price to sales ratio in the trailing 12-months stood at 0.8579.
Biofrontera Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $41.97 million
- Total Liabilities
- $20.45 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $14000
- Dividend Payout Ratio
- 0%
Biofrontera Inc ended 2024 with $41.97 million in total assets and $0 in total liabilities. Its intangible assets were valued at $41.97 million while shareholder equity stood at $16.75 million.
Biofrontera Inc ended 2024 with $0 in deferred long-term liabilities, $20.45 million in other current liabilities, 27000.00 in common stock, $-86997000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $13.51 million and cash and short-term investments were $21.10 million. The company’s total short-term debt was $484,000 while long-term debt stood at $0.
Biofrontera Inc’s total current assets stands at $37.22 million while long-term investments were $0 and short-term investments were $7.60 million. Its net receivables were $7.87 million compared to accounts payable of $1.80 million and inventory worth $6.67 million.
In 2024, Biofrontera Inc's operating cash flow was $0 while its capital expenditure stood at $14000.
Comparatively, Biofrontera Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $8.3
- 52-Week High
- $2.712
- 52-Week Low
- $0.37
- Analyst Target Price
- $10.5
Biofrontera Inc stock is currently trading at $8.3 per share. It touched a 52-week high of $2.712 and a 52-week low of $2.712. Analysts tracking the stock have a 12-month average target price of $10.5.
Its 50-day moving average was $10.02 and 200-day moving average was $13.09 The short ratio stood at 2.39 indicating a short percent outstanding of 0%.
Around 4239.2% of the company’s stock are held by insiders while 739.6% are held by institutions.
Frequently Asked Questions About Biofrontera Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.